Celldex Therapeutics Inc
(NAS:CLDX)
$
36.18
0.9 (2.55%)
Market Cap: 2.38 Bil
Enterprise Value: 1.50 Bil
PE Ratio: 0
PB Ratio: 2.84
GF Score: 62/100 - Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 TranscriptFeb 25, 2024
- Celldex Therapeutics Inc Conference Call & Webcast TranscriptNov 06, 2023
- Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Celldex Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria TranscriptFeb 26, 2023
- Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call TranscriptDec 06, 2022
- Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 TranscriptJun 30, 2022
- Q4 2021 Celldex Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$29.9 (-0.83%)Earnings
- Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 16, 2022
- Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call TranscriptJul 12, 2021
- Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update TranscriptMar 29, 2021
- Q2 2020 Celldex Therapeutics Inc Earnings Call TranscriptAug 06, 2020$11.71 (+1.39%)Earnings
- Celldex Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q2 2019 Celldex Therapeutics Inc Earnings Call TranscriptAug 07, 2019$2.16 (+3.85%)Earnings
- Q4 2018 Celldex Therapeutics Inc Earnings Call TranscriptMar 07, 2019$4.6 (-1.71%)Earnings
Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023 / 05:00PM GMT
Release Date Price:
$26.51
(+2.59%)
Kristen Kluska
Cantor Fitzgerald, L.P. - Analyst
All right. Good afternoon, everybody. Welcome to the afternoon session of the Cantor Healthcare Conference. Really happy to be with the Celldex team. We have Anthony Marucci, CEO; Dr. Diego Alvarado, Executive Director of Research; and Dr. Diane Young, CMO.
Thank you all so much for coming. I really appreciate it.
Diego Alvarado
Celldex Therapeutics, Inc. - Executive Director of Research
Thank you for inviting us. Glad to see you again.
Kristen Kluska
Cantor Fitzgerald, L.P. - Analyst
Yes. So our conference is well timed to this year because you have two data readouts expected before year end. After the success of your healthy volunteer and urticaria studies, we're going to see the first look at barzo, and a new indication, prurigo nodularis.
Questions & Answers
Kristen Kluska
Cantor Fitzgerald, L.P. - Analyst
To set the stage, why you believe this indication is relevant for mast cell targeting?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)